XML 159 R145.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Cash equivalents $ 2,234,000 $ 2,727,000 $ 2,234,000 $ 2,727,000 $ 3,209,000 $ 2,536,000
Restricted cash $ 201,000 $ 51,000 $ 201,000 $ 51,000 $ 50,000 $ 50,000
Concentration risk percentage 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Brooklyn Immunotherapeutics, LLC [Member]            
Cash equivalents $ 5,186,675   $ 5,186,675  
Restricted cash $ 86,000 $ 86,000 86,000 $ 86,000
Federal Deposit Insurance Corporation         $ 250,000  
Brooklyn Immunotherapeutics, LLC [Member] | Laboratory and Manufacturing Equipment [Member]            
Estimated useful life         7 years  
Brooklyn Immunotherapeutics, LLC [Member] | Laboratory and Manufacturing Equipment [Member] | Vendor [Member]            
Concentration risk percentage         14.00% 11.00%